228 related articles for article (PubMed ID: 12559677)
1. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment.
Hayashi K; Kumagai H; Saruta T
Am J Hypertens; 2003 Feb; 16(2):116-22. PubMed ID: 12559677
[TBL] [Abstract][Full Text] [Related]
2. Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats.
Shudo C; Masuda Y; Sugita H; Tamura T; Furukawa S; Hayashi K; Hirata H; Shikada K; Tanaka S; Tomita K
Arzneimittelforschung; 1996 Sep; 46(9):852-4. PubMed ID: 8876932
[TBL] [Abstract][Full Text] [Related]
3. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
[TBL] [Abstract][Full Text] [Related]
5. Efonidipine improves renal function and decreases proteinuria in elderly hypertensive patients in the JATOS study.
Okura T
Hypertens Res; 2010 Nov; 33(11):1112-3. PubMed ID: 20811385
[No Abstract] [Full Text] [Related]
6. Renal effects of efonidipine hydrochloride, a new calcium antagonist, in spontaneously hypertensive rats with glomerular injury.
Kawabata M; Ogawa T; Han WH; Takabatake T
Clin Exp Pharmacol Physiol; 1999 Sep; 26(9):674-9. PubMed ID: 10499155
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
Takai S; Jin D; Sakonjo H; Miyazaki M
Hypertens Res; 2010 Sep; 33(9):953-9. PubMed ID: 20520612
[TBL] [Abstract][Full Text] [Related]
8. Renal protection and antihypertensive drugs: current status.
Salvetti A; Mattei P; Sudano I
Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
Sasaki H; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohhira M; Oyama T; Miyashita Y; Shirai K
J Atheroscler Thromb; 2009 Oct; 16(5):568-75. PubMed ID: 19749494
[TBL] [Abstract][Full Text] [Related]
10. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine.
Hayashi K; Saruta T; Goto Y; Ishii M;
Hypertens Res; 2010 Nov; 33(11):1211-20. PubMed ID: 20844543
[TBL] [Abstract][Full Text] [Related]
11. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
12. Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR
Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
[TBL] [Abstract][Full Text] [Related]
13. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation.
Hayashi K; Wakino S; Homma K; Sugano N; Saruta T
J Pharmacol Sci; 2005 Nov; 99(3):221-7. PubMed ID: 16293936
[TBL] [Abstract][Full Text] [Related]
15. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats.
Fujiwara K; Kanno Y; Hayashi K; Takenaka T; Saruta T
Clin Exp Hypertens; 1998 Apr; 20(3):295-312. PubMed ID: 9605384
[TBL] [Abstract][Full Text] [Related]
16. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
Ruggenenti P; Perna A; Benini R; Remuzzi G
J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096
[TBL] [Abstract][Full Text] [Related]
17. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy.
Sugano N; Wakino S; Kanda T; Tatematsu S; Homma K; Yoshioka K; Hasegawa K; Hara Y; Suetsugu Y; Yoshizawa T; Hara Y; Utsunomiya Y; Tokudome G; Hosoya T; Saruta T; Hayashi K
Kidney Int; 2008 Apr; 73(7):826-34. PubMed ID: 18200001
[TBL] [Abstract][Full Text] [Related]
18. T-type Ca channel blockade as a determinant of kidney protection.
Hayashi K; Homma K; Wakino S; Tokuyama H; Sugano N; Saruta T; Itoh H
Keio J Med; 2010; 59(3):84-95. PubMed ID: 20881449
[TBL] [Abstract][Full Text] [Related]
19. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
20. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
Robles NR; Romero B; de Vinuesa EG; Sánchez-Casado E; Cubero JJ
Ren Fail; 2010 Jan; 32(2):192-7. PubMed ID: 20199181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
